Shifting PrEP Initiation from Practitioner to Nurse

1	Shifting PrEP Initiation from Practitioner to Nurse: a clinic-level multi-modal intervention
2	protocol to increase PrEP uptake among women at increased risk of HIV acquisition in a
3 1	U.S. OB/GYN clinical setting
4 5	Frin I. Gingher RN MS MHS
5	Timothee E Fruhauf MD MDH
7	Saumya S. Sao, BA
, 0	Sauniya S. Sao, DA Bunzhi Wang MD MUS
0	Ionall S. Calaman, MD, MPH*
9 10	Jenen S. Coleman, MD, MFTT
10	*Corresponding Author: Ispall Colomon colomoni@ihmi.edu
11	Corresponding Author. Jenen Coleman, <u>colemanj@jimit.edu</u>
12	Disclosures
13	Disclosures E.C. and I.C. wave funded in part by Cilard Sciences
14 15	E.G. and J.C. were funded in part by Gliead Sciences.
15	The remaining authors report no financial interests or potential conflicts of interest.
10	
1/	Acknowledgements
18	The authors would like to acknowledge the GYN/OB clinic staff for their assistance with this
19	study.
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	

Shifting PrEP Initiation from Practitioner to Nurse

42 Abstract

43	Women comprise 20% of new HIV diagnoses in the U.S. with 86% attributed to heterosexual
44	contact, but HIV pre-exposure prophylaxis (PrEP) uptake is low. OB/GYN clinics are ideal
45	settings to increase HIV prevention counseling for cisgender women, as patients are more likely
46	to discuss their sexual behavior, undergo sexually transmitted infection screening, and receive
47	risk reduction counseling. Our study will assess the feasibility, acceptability, and effectiveness of
48	a registered nurse (RN)-led PrEP project in OB/GYN clinics. Microlearning and Plan-Do-Study-
49	Act cycles will be performed, followed by a randomized controlled trial (RCT). A total of
50	cisgender women determined to be at-risk for HIV will be randomized to standard of care with
51	electronic medical record enhancements (e-SOC) or e-SOC with contact and PrEP counselling
52	by an RN, who will be able to prescribe PrEP under protocol guidance. By shifting HIV PrEP
53	counselling to a nurse, clinics may be able to increase PrEP awareness and uptake.
54	
55	Key words: pre-exposure prophylaxis (PrEP), HIV prevention, Ending the HIV Epidemic (EHE),

56 nurse, women

57

58 Registered with clinicaltrials.gov: NCT05095818

59	Shifting PrEP Initiation from Practitioner to Nurse: a clinic-level multi-modal intervention
60	protocol to increase PrEP uptake among women at increased risk of HIV acquisition in a
61	U.S. OB/GYN clinical setting
62	
63	Background
64	HIV remains a significant public health threat in the United States (U.S.). Despite
65	increased testing, prevention, and treatment services, the number of Americans newly infected
66	with HIV remains stable, with approximately 38,000 diagnosed each year (HIV.gov, 2021).
67	Women ¹ represent nearly one in five of these new diagnoses, and Black women are
68	disproportionately affected (60%) (Carley et al., 2019).
69	There are currently several effective HIV prevention strategies, including needle
70	exchange programs, consistent condom use, and prevention medications, such as pre-exposure
71	prophylaxis (PrEP) and post-exposure prophylaxis (PEP). In 2010, the iPrEx study reported
72	reduced risk of HIV acquisition with oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
73	among HIV-seronegative men and transgender women who have sex with men (Grant et al.,
74	2010). Shortly thereafter, the U.S. Food and Drug Administration (FDA) approved once daily
75	oral FTC/TDF as PrEP for HIV prevention in 2012 (FDA, n.d.). With high daily adherence, PrEP
76	is over 90% effective at preventing HIV acquisition. The U.S. Public Health Service released a
77	2021 clinical practice guideline update for PrEP that recommends informing all sexually active
78	adults and adolescents about PrEP. Despite the proven effectiveness of PrEP, utilization remains
79	low among heterosexual women. In 2018, only 7% of women in the U.S. who could benefit from
80	PrEP were prescribed it (CDC, 2021).

¹For the purposes of this paper, the term "women" will refer to people assigned female at birth

Shifting PrEP Initiation from Practitioner to Nurse

81	Multilevel barriers are associated with poor PrEP uptake among women. At the patient
82	level, barriers include minimal knowledge of PrEP and underestimation of HIV acquisition risk
83	(Aaron et al., 2018; Auerbach et al., 2015; Johnson et al., 2020; Ojikutu & Mayer, 2019). In a
84	study that surveyed urban obstetrics & gynecology (OB/GYN) clinics in Louisiana, the majority
85	of patients perceived their risk of HIV acquisition to be low, despite known risk factors, such as
86	inconsistent condom use with sexual activity in a region of high HIV prevalence (Carley et al.,
87	2019). Another study assessing the sexual behavior of pregnant women in Washington, D.C.
88	found no association between the number of behavioral risk factors and perceived risk of HIV
89	acquisition (Scott et al., 2021).
90	Once informed about PrEP, women express concern over potential side effects, dislike of
91	swallowing pills, and costs. The burden of frequent healthcare appointments and stigma
92	associated with taking a medication used by people living with HIV may also impede adoption
93	of PrEP (Collier et al., 2017; Hirschhorn et al., 2020). Interpersonal relationships, such as the
94	influence of sexual partners and practitioners, have also been identified as potential individual-
95	level barriers to PrEP (Ogunbajo et al., 2021)
96	Furthermore, barriers at the practitioner-level exist, including discomfort in taking a
97	sexual history, decreasing clinic visit length, competing clinical demands, and lack of knowledge
98	(O'Byrne et al., 2019). However, even when practitioners are knowledgeable about PrEP, uptake
99	is low. For example, in our own clinics, we found that approximately 10% of pregnant patients
100	were eligible for PrEP, but none were given prescriptions (Fruhauf & Coleman, 2017). With an
101	understanding of the PrEP barriers for heterosexual women and the federal government's Ending
102	the HIV Epidemic (EHE) Initiative, which aims to reduce the number of new HIV infections by

Shifting PrEP Initiation from Practitioner to Nurse

103	at least 90 percent by 2030, we sought to increase PrEP awareness and uptake in our outpatient
104	OB/GYN clinics.
105	This manuscript describes our clinic-level multi-modal intervention protocol to increase

106 HIV prevention services within OB/GYN clinical settings. We plan to conduct microlearning

107 sessions, Plan-Do-Study-Act cycles, and a pragmatic randomized controlled trial (RCT).

108

Methods

109 Setting

This project will be launched in three OB/GYN outpatient clinics of a single academic 110 111 medical system in Baltimore, Maryland, which has a Black majority population and a poverty rate of over 20% (U.S. Census Bureau, n.d.). In 2018, Baltimore City had an estimated HIV 112 incidence rate of 42.1 per 100,000 population (CDC, 2020). It is one of the 57 jurisdictions 113 114 targeted in the EHE Initiative (HIV.gov, 2020). The clinics offer general obstetric and 115 gynecologic care, with some providing specialized care for high-risk pregnancies. We selected 116 an outpatient OB/GYN setting because it is where women routinely receive STI counseling, 117 testing, and treatment. Data has shown that STIs increase the risk of HIV acquisition and 118 transmission (Ward & Rönn, 2010). Furthermore, HIV incidence among pregnant and postpartum women is 2-4 times higher than the rates outside of pregnancy, likely due to 119 120 behavioral and biological changes during this time period (Mugo et al., 2011; Thomson et al., 2018). Therefore, regularly scheduled obstetric and annual gynecologic visits are opportunities 121 122 for healthcare practitioners to discuss sexual health and HIV-risk behaviors with patients.

123 **Patients**

Patients will be included in the project if they are assigned female at birth, not living with
HIV, and are receiving OB/GYN care in our preselected clinics. Obstetric patients will be

Shifting PrEP Initiation from Practitioner to Nurse

126	identified through an existing non-validated STI/HIV risk assessment tool embedded into our
127	electronic medical record (EMR) (Table 1), which is completed by an RN during a patient's
128	initial prenatal care visit. This tool was developed over a decade ago as part of general
129	behavioral risk assessment for obstetrics patients, and not specifically for PrEP eligibility.
130	Eligible gynecologic patients will be identified by a positive STI diagnosis within the past 6
131	months, or if seeking STI testing and have a history of an STI (either self-reported or resulted in
132	the EMR). Because PrEP eligibility criteria (Table 2) differ by guidelines and expert opinion, we
133	selected broad criteria given the high HIV prevalence in our area (U.S. Public Health Service,
134	2018; The American College of Obstetricians and Gynecologists [ACOG], 2014). Before PrEP is
135	prescribed, PrEP contraindications will be followed, including: symptoms or clinical signs
136	consistent with acute HIV infection, unknown HIV infection status, allergies to the active
137	substances or any excipients of PrEP, estimated creatinine clearance of <60 mL/minute, active
138	Hepatitis B infection, or are participating in other clinical studies related to HIV and/or
139	antiretroviral therapy.

140 Study design

The study is designed with several, sequential methodologic components because of our 141 142 organizational culture and prior data that suggest complex, multi-level barriers to PrEP uptake 143 among women. First, we will synthesize the existing literature, engage key stakeholders, and conduct microlearning sessions about PrEP. Microlearning sessions involve the delivery of 144 educational content that is brief, targeted, and occur within clinical sites (Buchem & 145 Hamelmann, 2010). Microlearning sessions will be conducted among all healthcare team 146 147 members in the clinic, which includes nurses, medical assistants, nurse practitioners, midwives, and physicians. Then, Plan-Do-Study-Act (PDSA) will be used. The PDSA method is a 148

Shifting PrEP Initiation from Practitioner to Nurse

149	commonly used improvement process in health care settings, which utilizes small tests of change
150	to optimize a process (Coury et al., 2017). A common misperception with PDSA methodology is
151	that it is a standalone method (Reed & Card, 2016). Therefore, we designed multiple rigorous
152	methodologies to include along with PDSA.
153	The first PDSA cycle will involve EMR changes and identification of a registered nurse
154	(RN) who will be trained to initiate PrEP. Our prior data has shown that PrEP is rarely discussed
155	or prescribed to patients, despite indications (Fruhauf & Coleman, 2017; Lopez et al., 2019).
156	Proposed EMR changes will include the creation of (1) Best practice alerts (BPAs) that
157	encourage nurses and practitioners to add HIV risk-related ICD-10 codes to the problem lists.
158	Problem lists contain a summary snapshot of the patient's medical conditions for use by all
159	practitioners. A positive risk screen for prenatal care patients will alert the nurse to add "HIV
160	risk factors complicating pregnancy" to the patient's problem list during the initial prenatal visit.
161	When a patient tests positive for an STI and is prescribed an antibiotic for treatment, a BPA will
162	alert the GYN practitioner that the patient may have HIV acquisition risk factors and to add
163	"encounter for HIV counseling" to the problem list; (2) Comprehensive and easily accessible
164	order sets that facilitate initiation of PrEP by outlining the required laboratory tests and their
165	timing, and the exact FTC/TDF medication instructions to avoid incorrect prescriptions; (3) Note
166	templates that allow for consistent documentation and serve as an educational tool to ensure
167	adequate HIV prevention counseling is complete; (4) PrEP patient educational material to
168	include in patient after-visit summaries, which are given to patients at the conclusion of clinic
169	appointments. Educational materials include frequently asked questions (FAQ), FTC/TDF
170	medication facts, and PrEP use during pregnancy or breastfeeding; and (5) short animation
171	videos that describe PrEP.

Shifting PrEP Initiation from Practitioner to Nurse

172	We will identify a PrEP-RN who will undergo training in HIV prevention, including the
173	use of PrEP. Well within the scope of nursing practice, RNs can screen patients for risk factors,
174	counsel and educate at-risk patients about effective HIV prevention strategies, and advocate for
175	PrEP utilization. To our knowledge, this is the first U.S. RN-led PrEP program for women
176	exclusively. One novel aspect of our program is that our PrEP-RN will be able to initiate
177	laboratory test ordering and PrEP prescriptions, under specific protocol guidance and supervision
178	by the clinic's Medical Director. Another innovative aspect is that we designed our PrEP-RN
179	program to allow for telehealth counseling sessions for initiation and follow-up sessions via
180	telephone or video. Patients are only required to visit a brick-and-mortar location to complete
181	laboratory tests, which can take place at a location most convenient for them.
182	Other models for RN-led PrEP programs have been developed in Canada, but none focus
183	exclusively on women, take place in an OB/GYN outpatient setting where women prefer to
184	receive information about HIV prevention, or allow telehealth (Auerbach et al., 2015;
185	Hirschhorn et al., 2020; Sharma et al., 2018). As O'Byrne highlights in their PrEP-RN model,
186	the numerous appointments involved with the first year of PrEP use has a high potential for
187	missed appointments, which may be remedied by the use of telehealth (O'Byrne et al., 2019).
188	The second PDSA cycle will incorporate feedback from the first cycle and then deploy
189	the PrEP-RN intervention at the main outpatient clinic site. Subsequent PDSA cycles will
190	include roll-out of the project at the remaining clinical sites with protocol adjustments, as needed
191	based on the prior PDSA cycle. To test whether an RN can effectively counsel patients about
192	PrEP, initiate therapy, and follow patients with minimal practitioner involvement, we plan to
193	conduct a pragmatic randomized controlled trial (RCT). A pragmatic (effectiveness) trial was
194	selected to generate evidence that would be applicable in a real-world clinical practice setting

Shifting PrEP Initiation from Practitioner to Nurse

and increase external validity. The control arm will include an enhanced standard of care (eSOC), which is standard of care plus the EMR changes. The intervention arm will include the
PrEP-RN plus e-SOC.

Patients randomized to the intervention arm will first be contacted via an electronic patient portal integrated with the EMR that allows patients access to their medical records and a messaging system to communicate with practitioners. While most of our patients utilize this patient portal, if a patient does not have access, this step will be skipped.

Follow-up telephone calls will then be made to counsel patients on HIV risk factors in 202 general, their HIV risk factors in particular, and prevention methods, inclusive of PrEP. PrEP, 203 including same-day PrEP, will be offered. If the required laboratory tests have not been obtained 204 in the past month, the PrEP-RN will place and order the laboratory tests. The PrEP-RN will 205 206 utilize the PrEP order set in the EMR to order labs, prescribe medication electronically to the patient's pharmacy, provide patient education, and schedule follow-up appointments. All orders 207 208 and prescriptions are sent to the clinic's Medical Director for authorization. Standardized 209 smartphrases for clinical notes will also be utilized to record the interaction by the PrEP-RN with the study participants. 210

If a patient declines PrEP, no further attempts are made by the PrEP-RN to counsel the patient. Additional educational material may be sent via the electronic patient portal as desired by the patient. The patient is encouraged to contact the PrEP-RN, via telephone or the electronic patient portal, if she has any future questions or decides to use PrEP.

A Manual of Procedures (**Appendix A**) was created for the PrEP-RN to carry out each step of PrEP initiation and follow up. The manual outlines how to respond to abnormal tests, provide prescription coverage assistance, and coordinate care with other specialties as needed to

Shifting PrEP Initiation from Practitioner to Nurse

address test results. The PrEP-RN will be responsible for follow-up visits and will contact the
patients one-two weeks after medication initiation. At this time, the PrEP-RN will review the
importance of daily adherence to PrEP and assess for any side effects.

221 Randomization and blinding

Stratified block randomization will be used to allocate eligible patients into the 222 intervention and control arms with a 1:1 ratio. Patients will be classified by patient type 223 224 (obstetric or gynecologic) and clinics. To avoid imbalance between the two study arms, the same 225 type of patients from the same site will be randomized within a block that comprise four ordered assignments. SAS will be used to generate the randomization table. EMR data abstracts will be 226 obtained biweekly to identify PrEP eligible patients. A member of the study team will assign 227 these PrEP eligible patients to an intervention arm based on the randomization allocation per 228 229 patient type and site. Practitioners will be blinded to study assignment to prevent interference in

the standard of care delivery.

231 Ethics Approval and Waiver of Consent to Participate

The study received approval from the Institutional Review Board (IRB) of Johns Hopkins Medicine. Although the primary purpose of the project was to improve patient outcomes, the IRB reviewed the project as research because we included randomization plus an external funding source. However, a waiver of consent was granted because the study involves no more than minimal risk to the subjects, the waiver does not adversely affect the rights or welfare of the subjects, and the research could not be practicably completed without the waiver.

238 Sample size estimate

To test the effectiveness of the PrEP-RN, we estimate that we will require 440 patients (220 women per arm). The sample size was selected to provide 80% power to detect an effect

Shifting PrEP Initiation from Practitioner to Nurse

241 size of 15% between the control and intervention group, at an alpha level of 0.05 using two-sided 242 test. The PrEP-RN intervention and EMR prompts will cease once the sample size has been 243 reached. 244 **Outcomes** The project will be evaluated using the Reach, Effectiveness, Adoption, Implementation, 245 and Maintenance (RE-AIM) framework. RE-AIM has five domains: Reach the target population 246 247 with the intervention; Effectiveness or impact of the intervention; Adoption by target patients, 248 staff, clinics; Implementation of the intervention, including consistency of delivery; and Maintenance of the intervention over the long term (RE-AIM, n.d.). The Reach and 249 Effectiveness domains are individual-level factors, while the Adoption and Implementation 250 domains are systems-level factors. The Maintenance domain includes both individual- and 251 252 systems-level factors. 253 **Primary Outcomes** The primary outcome estimated by the RCT will be awareness of PrEP, measured by the 254 255 percentage of at-risk women with EMR documentation of HIV risk prevention counseling. **Secondary Outcomes** 256 Secondary outcomes will include feasibility, which will be defined as reaching the target 257 258 goal in at least 3 of the RE-AIM domains (**Table 3**). Other secondary outcomes include the 259 percentage of women at risk for HIV who initiate PrEP during the study interval and the percentage of women who are using PrEP at 3-, 6-, 9-, and 12-months from initiation. PrEP 260 initiation will be measured by the number of PrEP laboratory tests and the number of PrEP 261 262 prescriptions ordered. We will also assess the utilization of EMR enhancements, measured as the

Shifting PrEP Initiation from Practitioner to Nurse

263	percentage of	patients with an	HIV-risk diagno	osis added to their	r EMR	problem list. Last	, we will
-----	---------------	------------------	-----------------	---------------------	-------	--------------------	-----------

evaluate the acceptability of the PrEP-RN intervention among our study population.

265 Acceptability

- Acceptability of and satisfaction with the PrEP-RN intervention will be evaluated using a
- brief survey of a randomly selected group of patients (n=25) who received the PrEP-RN
- intervention within the previous three months (**Table 4**). Items related to patient satisfaction and
- telehealth acceptability were identified through a review of the literature (Weaver et al., 2021;
- 270 Yip et al., 2003; Gwadry-Sridhar et al., 2003).

271 Risks and monitoring

The intervention does not pose any greater risks than routine clinical care, and no participant will receive less than e-SOC. Because the intervention is integrated at the clinic level and poses minimal risk, we do not have an independent data monitoring committee. The team will report any adverse events to the IRB. To ensure the quality of our counseling intervention, we will have weekly check-ins with the PrEP RN, research staff, and the study Principal Investigator to discuss any issues in counseling patients and incorporate patient feedback on an ongoing basis.

279

Statistical Analysis

Sociodemographic characteristics of the study population will be reported using descriptive statistics. For the RCT, statistical analysis will be performed based on the intentionto-treat principle. We will compare the percentage of at-risk women with EMR documentation of HIV risk prevention counseling (i.e. primary outcome), percentage of women at risk for HIV who initiate PrEP during the study interval, and the percentage of women who are using PrEP at 3-, 6-, 9-, and 12-months from initiation between the intervention group and the control group

286	using the chi-squared test with Fisher's exact. Since participants in the two arms are expected to
287	have equal baseline characteristics due to randomization, basic confounders will not be
288	considered. However, if any baseline characteristics differ significantly between the two groups,
289	we will use regression models to control them. Additionally, among women randomized to the
290	PrEP RN, the reason for initiating or not initiating PrEP will be presented as a number and
291	percentage. Also, we will plot the percentage of women who are using PrEP for 3-, 6-, 9-, and
292	12-months to demonstrate the trend. Marginal models will be used to identify factors associated
293	with the trend. Lastly, to assess whether the interventions had a sustainable impact on
294	practitioners' behavior after withdrawing them, the primary and secondary outcomes will be
295	compared to the year before the PrEP RN project began, using the chi-squared test.
296	Discussion
297	Prevention is one of the four key strategies outlined by the federal government's EHE
298	initiative. Our novel project seeks to prevent new HIV transmissions by addressing known
299	barriers to PrEP at the patient, practitioner, and system levels.
300	OB/GYN clinics were chosen for this project for several reasons. First, women have
301	consistently expressed a preference for receiving HIV prevention services in clinics where they
302	receive OB/GYN care, as opposed to specialty clinics that treat infectious diseases or STIs where
303	most PrEP projects are located (Auerbach et al., 2015; Carley et al., 2019; Hirschhorn et al.,
304	2020). Second, despite a history of mistrust in the health care system, Black and Hispanic
305	women reported trusting their individual gynecologist (Hirschhorn et al., 2020; Kennedy et al.,
306	2007). Third, PrEP use by women in the U.S. is largely inadequate, as the PrEP-to-need ratio for
307	women is only 0.4 compared to 2.1 for men (Highleyman, 2018). Last, OB/GYN practitioners
308	manage women during heightened periods of HIV acquisition risk, such as during the course of

Shifting PrEP Initiation from Practitioner to Nurse

309	infection with an STI or during pregnancy and the postpartum period, and they routinely provide
310	sexual and reproductive care for at-risk women (ACOG, 2018).
311	Clinic nurses are well suited for PrEP counseling sessions, as they are accustomed to
312	delivering positive STI results to patients and providing risk reduction strategies. Furthermore,
313	registered nurses represent a more abundant and less expensive resource than physicians or mid-
314	level providers (American Association of Colleges of Nursing, 2019).
315	Through the role of the PrEP RN, we are utilizing telemedicine to help combat barriers to
316	PrEP awareness and initiation. Telemedicine may improve efficiency, while also providing
317	increased comfort and convenience for patients. Barriers to patient access, such as limited time
318	off from work and childcare responsibilities are minimized (Hasselfeld, n.d.; Gajarawala &
319	Pelkowski, 2021). Feasibility and efficacy, as well as patient acceptability, will be evaluated to
320	determine the overall success of the project.
321	Despite the strengths, our protocol has several limitations. Our health system has EMRs,
322	which facilitates the ease of nursing staff to place orders and prescriptions to be signed by a
323	practitioner. Systems without EMRs may find our protocol cumbersome, however, standing
324	orders may be considered instead. It is also plausible that changes in PrEP uptake could be due in
325	part to practitioner behavior changes resulting from the EMR enhancements, as opposed to the
326	PrEP-RN. Furthermore, by targeting female patients who are engaged in clinical care, we are
327	unable to reach women at-risk for HIV who do not have access to routine care. Lastly, our urban
328	high HIV prevalence location may limit the generalizability of this study.
329	Nonetheless, if this study demonstrates that a PrEP-RN can increase PrEP awareness and
330	uptake among at-risk women, we plan to test these interventions, including the EMR
331	enhancements in non-OB/GYN clinical settings. Our multimodal PrEP intervention could be

- implemented in other settings and largely improve current strategies for increasing PrEP
- 333 utilization among at-risk women.

334	References
335	Aaron, E., Blum, C., Seidman, D., Hoyt, M. J., Simone, J., Sullivan, M., & Smith, D. K. (2018).
336	Optimizing delivery of HIV preexposure prophylaxis for women in the United States.
337	AIDS Patient Care and STDs, 32(1), 16-23. https://doi.org/10.1089/apc.2017.0201
338	American Association of Colleges of Nursing (AACN). (2019, April 1). Nursing fact sheet.
339	https://www.aacnnursing.org/News-Information/Fact-Sheets/Nursing-Fact-Sheet
340	Auerbach, J. D., Kinsky, S., Brown, G., & Charles, V. (2015). Knowledge, attitudes, and
341	likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring
342	HIV. AIDS Patient Care and STDs, 29(2), 102–110.
343	https://doi.org/10.1089/apc.2014.0142
344	Buchem, I., & Hamelmann, H. (2010, September). Microlearning: A strategy for ongoing
345	professional development. eLearning Papers.
346	Carley, T., Siewert, E., & Naresh, A. (2019). Interest in pre-exposure prophylaxis (PrEP) for
347	HIV is limited among women in a general obstetrics & gynecology setting. AIDS and
348	Behavior, 23(10), 2741-2748. https://doi.org/10.1007/s10461-019-02529-1
349	Centers for Disease Control and Prevention (CDC). (2020, May). Estimated HIV incidence and
350	prevalence in the United States, 2014–2018. HIV Surveillance Supplemental Report
351	2020; 25(No. 1). http://www.cdc.gov/ hiv/library/reports/hiv-surveillance.html
352	Centers for Disease Control and Prevention (CDC). (2021, March 8). HIV and women.
353	https://www.cdc.gov/hiv/group/gender/women/prep-coverage.html

- 354 Collier, K. L., Colarossi, L. G., & Sanders, K. (2017). Raising Awareness of Pre-Exposure
- 355 Prophylaxis (PrEP) among Women in New York City: Community and Provider
- 356 Perspectives. *Journal of Health Communication*, 22(3), 183–189.
- 357 https://doi.org/10.1080/10810730.2016.1261969
- 358 Coury, J., Schneider, J. L., Rivelli, J. S., Petrik, A. F., Seibel, E., D'Agostini, B., Taplin, S. H.,
- 359 Green, B. B., & Coronado, G. D. (2017). Applying the Plan-Do-Study-Act (PDSA)
- approach to a large pragmatic study involving safety net clinics. *BMC Health Services*
- 361 *Research*, Aaron, E., Blum, C., Seidman, D., Hoyt, M. J., Simone, J., Sullivan, M., &
- 362 Smith, D. K. (2018). Optimizing Delivery of HIV Preexposure Prophylaxis for Women in
- the United States. *AIDS Patient Care and STDs*, *32*(1), 16–23.
- 364 https://doi.org/10.1089/apc.2017.0201
- Fruhauf, T., & Coleman, J. S. (2017). A missed opportunity for U.S. perinatal Human
- Immunodeficiency Virus elimination. *Obstetrics and Gynecology*, *130*(4), 703–709.
- 367 https://doi.org/10.1097/AOG.0000000002258
- 368 Gajarawala, S. N., & Pelkowski, J. N. (2021). Telehealth Benefits and Barriers. *The Journal for*
- 369 *Nurse Practitioners*, *17*(2), 218–221. https://doi.org/10.1016/j.nurpra.2020.09.013
- Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P.,
- 371 Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., Montoya-Herrera, O.,
- Fernández, T., Veloso, V. G., Buchbinder, S. P., Chariyalertsak, S., Schechter, M.,
- Bekker, L.-G., Mayer, K. H., Kallás, E. G., ... Glidden, D. V. (2010). Preexposure
- 374 chemoprophylaxis for HIV prevention in men who have sex with men. *New England*
- 375 *Journal of Medicine*, *363*(27), 2587–2599. https://doi.org/10.1056/NEJMoa1011205

Shifting PrEP Initiation from Practitioner to Nurse

- 376 Gwadry-Sridhar, F., Guyatt, G. H., Arnold, J. M. O., Massel, D., Brown, J., Nadeau, L., &
- Lawrence, S. (2003). Instruments to measure acceptability of information and acquisition
- of knowledge in patients with heart failure. *European Journal of Heart Failure*, 5(6),
- 379 783–791. https://doi.org/10.1016/S1388-9842(03)00158-2
- Hasselfeld, B.W. (n.d.). *Benefits of Telemedicine*. Johns Hopkins Medicine Health.
- 381 https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/benefits-of-
- 382 telemedicine
- Highleyman, L. (2018, March 7). PrEP use growing in US, but not reaching all those in need.
- NAM: AIDSmap. https://www.aidsmap.com/news/mar-2018/prep-use-growing-us-not reaching-all-those-need
- Hirschhorn, L. R., Brown, R. N., Friedman, E. E., Greene, G. J., Bender, A., Christeller, C.,
- Bouris, A., Johnson, A. K., Pickett, J., Modali, L., & Ridgway, J. P. (2020). Black
- cisgender women's PrEP knowledge, attitudes, preferences, and experience in Chicago.
- *Journal of Acquired Immune Deficiency Syndrome*, 84(5), 497-507.
- 390 <u>https://doi.org/10.1097/QAI.00000000002377</u>...
- HIV.gov. (2021, June 2). What is Ending the HIV Epidemic in the U.S.?

392 https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview

- HIV.gov. (2020, November 3). Priority Jurisdictions: Phase I. https://www.hiv.gov/federal-
- 394 response/ending-the-hiv-epidemic/jurisdictions/phase-one
- Johnson, A. K., Fletcher, F. E., Ott, E., Wishart, M., Friedman, E. E., Terlikowski, J., & Haider,
- 396 S. (2020). Awareness and Intent to Use Pre-exposure Prophylaxis (PrEP) Among African

207	· ·	XX 7	• • •	1 1 1		CD 1	1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -
247	$\Delta merican$	W/omen	in a Hami	IV Planning	1 11n1c Lournal (nt Racial av	nd Hthmic Hoalth
557	American	w onion.	iii a i aiiii	iy i iammi	c_{mnc} , j_{0nma}	η matual α	

- 398 *Disparities*, 7(3), 550–554. https://doi.org/10.1007/s40615-019-00683-9
- 399 Kennedy, B. R., Mathis, C. C., & Woods, A. K. (2007). African Americans and their distrust of
- 400 the health care system: Healthcare for diverse populations. *Journal of Cultural Diversity*,
- 401 14(2), 56–60.
- 402 Lopez, A., Belcher, H., Agwu, A. L., Fennell, J. C., Gaydos, C., & Trent, M. E. (2019). 51.
- 403 Unmet need for risk reduction counseling and Prep among young women at risk for HIV.
- 404 *Journal of Adolescent Health*, 64(2), S28.
- 405 https://doi.org/10.1016/j.jadohealth.2018.10.066
- 406 Mugo, N., Heffron, R., Donnell, D., Wald, A., Were, E., Rees, H., Celum, C., Kiarie, J., Cohen,
- 407 C., Kayintekore, K., Baeten, J. Increased risk of HIV-1 transmission in pregnancy: A
- 408 prospective study among African HIV-1 serodiscordant couples. *AIDS*, 25(15), 1887-
- 409 1895. doi:10.1097/QAD.0b013e32834a9338.
- 410 O'Byrne, P., MacPherson, P., Orser, L., Jacob, J. D., & Holmes, D. (2019). PrEP-RN: Clinical
- 411 considerations and protocols for nurse-led PrEP. *The Journal of the Association of Nurses*
- 412 *in AIDS Care*, *30*(3), 301–311. https://doi.org/10.1097/JNC.000000000000075
- 413 Ogunbajo, A., Storholm, E. D., Ober, A. J., Bogart, L. M., Reback, C. J., Flynn, R., Lyman, P.,
- 414 & Morris, S. (2021). Multilevel Barriers to HIV PrEP Uptake and Adherence Among
- 415 Black and Hispanic/Latinx Transgender Women in Southern California. *AIDS and*
- 416 *Behavior*, 25(7), 2301–2315. https://doi.org/10.1007/s10461-021-03159-2

- 417 Ojikutu, B. O., & Mayer, K. H. (2019). Hidden in Plain Sight: Identifying Women Living in the
- 418 United States Who Could Benefit From HIV Preexposure Prophylaxis. *The Journal of*
- 419 Infectious Diseases, 222(9), 1428–1431. https://doi.org/10.1093/infdis/jiz416
- 420 RE-AIM. (n.d.) What is RE-AIM. https://www.re-aim.org/about/what-is-re-aim/
- 421 Reed, J. E., & Card, A. J. (2016). The problem with Plan-Do-Study-Act cycles. BMJ Quality &
- 422 Safety, 25(3), 147–152. https://doi.org/10.1136/bmjqs-2015-005076
- 423 Scott, R. K., Hull, S. J., Richards, R. C., Klemmer, K., Salmoran, F., & Huang, J. C. (2021).
- 424 Awareness, acceptability, and intention to initiate HIV pre-exposure prophylaxis among
- 425 pregnant women. *AIDS Care*, 1–13. https://doi.org/10.1080/09540121.2021.1916870
- 426 Sharma, M., Chris, A., Chan, A., Knox, D. C., Wilton, J., McEwen, O., Mishra, S., Grace, D.,
- 427 Rogers, T., Bayoumi, A. M., Maxwell, J., Shahin, R., Bogoch, I., Gilbert, M., & Tan, D.
- 428 H. S. (2018). Decentralizing the delivery of HIV pre-exposure prophylaxis (PrEP)
- 429 through family physicians and sexual health clinic nurses: A dissemination and
- 430 implementation study protocol. *BMC Health Services Research*, 18(1), 513.
- 431 https://doi.org/10.1186/s12913-018-3324-2
- 432 The American College of Obstetricians and Gynecologists (ACOG). (2018, October). Well-
- 433 woman visit. ACOG Committee Opinion, 755. https://www.acog.org/en/clinical/clinical-
- 434 guidance/committee-opinion/articles/2018/10/well-woman-visit
- The American College of Obstetricians and Gynecologists (ACOG). (2014, May; reaffirmed
- 436 2020). Preexposure prophylaxis for the prevention of Human Immunodeficiency Virus.
- 437 ACOG Committee Opinion, 595. https://www.acog.org/en/clinical/clinical-

Shifting PrEP Initiation from Practitioner to Nurse

- 438 guidance/committee-opinion/articles/2014/05/preexposure-prophylaxis-for-the-
- 439 prevention-of-human-immunodeficiency-virus
- 440 Thomson, K., Hughes, J., Baeten, J., John-Stewart, G., Celum, C., Cohen, C., Ngure, K., Kiarie,
- 441 J., Mugo, N., Heffron, R. (2018). Increased risk of HIV acquisition among women
- throughout pregnancy and during the postpartum period: A prospective per-coital-act
- 443 analysis among women with HIV-infected partners. *The Journal of Infectious Diseases;*
- 444 218(1), 16–25, https://doi.org/10.1093/infdis/jiy113

445 U.S. Census Bureau. (n.d.) *QuickFacts: Baltimore city, Maryland; United States.*

- 446 https://www.census.gov/quickfacts/fact/table/baltimorecitymaryland,US/PST045219
- 447 U.S. Food & Drug Administration (FDA). (n.d.) Drugs@FDA: FDA-Approved Drugs.
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&Ap
 plNo=021752
- 450 U.S. Public Health Service. (published online 2018, March). Preexposure prophylaxis for the
- 451 prevention of HIV infection in the United States 2017 Update. A Clinical Practice
- 452 Guideline. <u>https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf</u>
- 453 U.S. Public Health Service. (2021). Preexposure prophylaxis for the prevention of HIV infection

454 in the United States – 2021 Update. A Clinical Practice Guideline.

- 455 https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf
- 456 Ward, H., & Rönn, M. (2010). The contribution of STIs to the sexual transmission of HIV.
- 457 *Current Opinion in HIV and AIDS*, 5(4), 305–310.
- 458 https://doi.org/10.1097/COH.0b013e32833a8844

Shifting PrEP Initiation from Practitioner to Nurse

- 459 Weaver, M. S., Lukowski, J., Wichman, B., Navaneethan, H., Fisher, A. L., & Neumann, M. L.
- 460 (2021). Human connection and technology connectivity: A systematic review of available
- telehealth survey instruments. *Journal of Pain and Symptom Management*, 61(5), 1042-
- 462 1051.e2. https://doi.org/10.1016/j.jpainsymman.2020.10.010
- 463 Yip, M.P., Chang, A.M., & Chan, J. (2003, February 1). Development of the telemedicine
- satisfaction questionnaire to evaluate patient satisfaction with telemedicine: A
- 465 preliminary study. *Journal of Telemedicine and Telecare*, 9(1), 46–50.
- 466 https://doi.org/10.1258/135763303321159693

468		Key Considerations
469	•	There are many reasons why PrEP uptake among American women is so low, with
470		underestimation of HIV acquisition risk a major factor.
471	•	HIV risk factor and prevention counseling can take place via telemedicine, which has
472		increasingly become a popular and convenient method of healthcare delivery.
473	•	The EMR can be utilized to alert practitioners to HIV risk factors and aid in the
474		identification of PrEP-eligible patients.
475		

Shifting PrEP Initiation from Practitioner to Nurse

476 Table 1: Obstetric HIV/STI Risk Tool

Risk factor		Response options	
Inject illicit drugs	Yes, in the past 6 months	Yes, more than 6 months ago	Never
Sex with partner who injects illicit drugs	Yes, in the past 6 months	Yes, more than 6 months ago	Never
Any past STIs	Yes, in the past 6 months	Yes, more than 6 months ago	Never
Sex with a partner who has sex with both men and women	Yes, in the past 6 months	Yes, more than 6 months ago	Never
Sex for money, drugs, other payment	Yes, in the past 6 months	Yes, more than 6 months ago	Never
Sex with a partner currently infected with HIV	Yes, in the past 6 months	Yes, more than 6 months ago	Never
Sex with more than one partner	Yes, in the past 6 months	Yes, more than 6 months ago	Never

Shifting PrEP Initiation from Practitioner to Nurse

478 Table 2: PrEP Eligibility Criteria by Organization

Risk Factors	ACOG	CDC	USPSTF	WHO*
Sex in high HIV- prevalence area or social network (plus at least one other risk factor)	· ✓		-	_
Inconsistent or no condom use	\checkmark	\checkmark	✓ (inconsistent condom	\checkmark
Sexual partner with unknown HIV status	✓ (who has at least one other risk factor)		use with a partner whose HIV status is unknown and who is at high risk, such as injection drug user or man who has sex with men and women)	✓ (and partner is high risk)
Sexual partner living with HIV	✓	✓	\checkmark	✓
STI diagnosis within past 6 months	✓ (no time frame)	√	✓ (syphilis or gonorrhea)	√
Injection drug use	 ✓ 	✓ (with shared injection equipment or injection partner with HIV)	(with shared drug injection equipment or risk of sexual acquisition)	✓ (with shared needles/syringes)
Recreational drug use			✓ (with shared drug injection equipment or risk of sexual acquisition)	✓ (sex under the influence of recreational drugs)
Alcohol dependence	√			✓ (sex under the influence of alcohol)
Incarceration	\checkmark			,
Transactional sex	✓			✓
Ongoing IPV/GBV				\checkmark
Recurrent use of PEP		✓		✓
ACOG: The American C CDC: Centers for Disea USPSTF: United States WHO: World Health On IPV: intimate partner vi GBV: gender-based vio	College of Obstetricians and se Control and Prevention Preventive Services Task rganization olence lence	nd Gynecologists Force		

PEP: post-exposure prophylaxis *According to WHO, PrEP eligibility may vary by

*According to WHO, PrEP eligibility may vary by country. HIV-negative individuals who are "determined to be at substantial risk for HIV as defined by national guidelines" are eligible for PrEP. WHO does not list specific criteria but offers an example tool for determining eligibility. These example criteria are included in the table.

479

480

Shifting PrEP Initiation from Practitioner to Nurse

482

483 Table 3. Re-AIM Evaluation

Domain	Target	
REACH		
% women with documented HIV risk counseling, including PrEP (awareness)	$\geq \! 80\%$	
EFFECTIVENESS		
% women at-risk for HIV who agree to PrEP (uptake: PrEP lab orders and prescriptions)	≥50%	
% women at-risk for HIV who agree to same-day PrEP	≥30%	
ADOPTION		
% of nurses adding HIV risk diagnosis to problem list	≥ 20	
IMPLEMENTATION		
% pregnant women with completed HIV risk screen randomized	≥90%	
% at-risk pregnant women with diagnosis on problem list	$\geq \! 80\%$	
% STI positive women randomized	≥90%	
% STI positive women in intervention arm contacted by PrEP nurse	≥75%	
MAINTENANCE		
% women at-risk for HIV using PrEP x 3 months	≥35%	
% women at-risk for HIV using PrEP x 6 months	≥25%	
% women at-risk for HIV using PrEP x 12 months	≥15%	

Shifting PrEP Initiation from Practitioner to Nurse

Table 4. PrEP RN Patient Acceptability Questionnaire 485

486

Qı	uestion	Response Options
1.	Have you ever heard about PrEP (pre- exposure prophylaxis) for HIV?	 Yes No (skip to Q6)
2.	If yes, who provided the information?	 Doctor Nurse Friend Family member Other healthcare provider Uncertain
3.	Did they help you better understand your risk for HIV acquisition?	No, not at all (1) (2) (3) (4) (5) Yes, very much
4.	Did they help you better understand HIV prevention methods, including PrEP?	No, not at all (1) (2) (3) (4) (5) Yes, very much
5.	How well do you think that you understand PrEP?	Know very little (1) (2) (3) (4) (5) Very knowledgeable
Fo sp	or patients indicating that they received in ecifically pertain to the telephone counsel	formation from a <u>nurse</u> , these questions will ing session:
6.	Do you remember receiving a phone call providing information about PrEP?	 Yes No (skip to Q8)
7.	How useful was the information received from the nurse?	Not at all useful (1) (2) (3) (4) (5) Very useful
8.	Were you satisfied with the telephone	No, not at all (1) (2) (3) (4) (5) Yes, very much

method of delivery for this information? 1 1 1 1 1 1 .

9.	How would you have liked to be
	contacted with this information (e.g., in
	person appointment, video visit)?

- 10. Please rate your overall satisfaction Very dissatisfied (1) (2) (3) (4) (5) Very satisfied with the counseling sessions.
- 11. Do you have any additional comments?

488	APPENDIX A
489	PrEP RN Manual
490	The decision to prescribe PrEP is based on the clinical judgment of the nurse evaluating
491	the patient. The following is a list of steps to be followed by the PrEP RN.
492	a) <u>Determine Eligibility</u>
493	Women (assigned female at birth) ≥ 15 years old at risk for HIV infection should be
494	considered for PrEP and will be assessed for the option of same-day PrEP start.
495	• Living in (or seeking medical care) in a high HIV-prevalence area or social
496	network
497	• Inconsistent or no condom use
498	• Specific criteria for patient type:
499	• GYN patients:
500	 current or recent (within last six months) STI diagnosis
501	 lifetime history of STI and currently seeking STI testing
502	• OB patients: lifetime history of at least one of the following:
503	 STI diagnosis
504	 More than one concurrent sexual partner
505	 Injection of illicit drugs
506	 Sex with someone who injects illicit drugs
507	 Sex with someone who has sex with both men and women
508	 Sex with a partner currently living with HIV
509	 Sex for money, drugs, or other payments

510	•	If a patient is PEP (post-exposure prophylaxis)-eligible based on clinical
511		guidelines, including exposure within the past 72 hours, the patient should be
512		started on PEP and transitioned to PrEP after 1 month. Upon transition from PEP
513		to PrEP the patient needs to be reassessed for clinical signs of HIV infection and
514		labs for PrEP start need to be obtained.
515	٠	If a patient has any of the following conditions, she is not a candidate for PrEP:
516		 unknown or known HIV infection
517		 renal insufficiency (CrCl <60ml/min)
518		 active Hepatitis B infection
519		 signs or symptoms of acute HIV infection
520		\circ not able to strictly adhere to the treatment or monitoring protocols
521		• weight<35 kg
522		o allergies to the active substances or any excipients of PrEP
523		• taking PEP or other antiretroviral therapy
524	•	If a patient meets both of the following criteria for possible acute HIV syndrome,
525		they will not be candidates for same-day start:
526		\circ High risk exposure to HIV within the past 6 weeks
527		• Clinical signs and symptoms (currently or within the past 2 weeks) of acute
528		HIV infection, including fever, lymphadenopathy, rash, diarrhea, oral ulcers,
529		myalgia/arthralgia
530	b) <u>Sa</u>	ame-Day-PrEP-Start
531	•	If a patient is found eligible for same-day-PrEP start, a 4 th generation rapid HIV test
532		needs to be performed.

533		• If negative, all PrEP initiating labs will be ordered.
534		o If positive, a 4th generation HIV Antibody/Antigen and HIV viral load test
535		should be ordered
536		 Patient is referred to Adult HIV Clinic immediately for ART
537	•	Exclusion criteria for same day PrEP are:
538		• Positive HIV test or clinical signs and symptoms of possible acute HIV
539		syndrome, or possible exposure to HIV within the past 72 hours
540		• No insurance. Patient will meet with case manager to discuss insurance
541		eligibility.
542		\circ Age >50 years AND no renal function test within the past 6 months on file
543		• No working telephone number
544	•	If patient found to eligible and interested in same-day-PrEP start, 30 days of PrEP will
545		be ordered per protocol and pended for signature by the Medical Director.
546	•	Patient will be counseled that there is a risk that PrEP must be stopped if labs reveal
547		any abnormalities, such as renal impairment, in which case patient will receive a call
548		by the nurse.
549	•	If the patient has sexual or drug partners who are known to be HIV infected, the nurse
550		should attempt to determine whether these partners are receiving antiretroviral therapy
551		and assist with linkage to care for these partners if they are not in care or not receiving
552		antiretroviral therapy.
553	c) <u>L</u>	Delayed-PrEP-Start
554	•	If decision is made not to start PrEP on the same day routine PrEP initiation labs are
555		ordered:

556	• If the patient has symptoms consistent with acute HIV infection OR if the patient
557	has had a risky exposure (injection drug use, unprotected intercourse) in the last
558	three weeks, an HIV viral load test will be drawn, in addition to a 4th generation
559	HIV Antibody/Antigen test
560	• Patients without signs of acute HIV infection, a 4th generation HIV
561	Antibody/Antigen test will be drawn
562	• Patients will be advised to remain abstinent until they begin PrEP.
563	• The nurse will confirm that the patient's calculated creatinine clearance is greater than or
564	equal to 60 mL/minute (via Cockcroft-Gault formula).
565	• If lower than 60 mL/minute, notify Medical Director
566	d) <u>All Patients Starting on PrEP</u>
567	• The nurse will screen for HBV infection and vaccinate against HBV if susceptible, or
568	treat if active infection exists, regardless of the decision about prescribing PrEP.
569	• The nurse will screen and coordinate treatment, as needed, for STIs.
570	• The nurse will review and confirm potential drug interactions.
571	• In women of reproductive age or transmales who have sex with males, the nurse will:
572	• screen for pregnancy with a urine HCG test.
573	• determine if patient is planning to become pregnant or if patient is breastfeeding.
574	e) <u>Beginning PrEP Medication Regimen</u>
575	After reviewing all lab work to confirm a patient is appropriate for PrEP, the nurse will:
576	• Order 1 tablet of Truvada (TDF 300mg plus FTC 200mg) by mouth daily.
577	• Prescribe no more than a 90-day supply, renewable only after HIV testing
578	confirms that a patient remains HIV-uninfected.

579	• Route the order to the Medical Director for signing
580	$\circ~$ If active HBV infection is diagnosed, the nurse will notify Medical Director/
581	refer to Infectious Disease Specialist
582	• Provide risk-reduction and PrEP medication adherence counseling and condoms.
583	• Confirm patient's insurance coverage. Refer uninsured patients or patients with high
584	prescription co-pays to https://www.pleaseprepme.org/payment
585	• Place ICD 10 Code on problem list (Encounter for HIV counseling; HIV risk factors
586	affecting pregnancy)
587	• Educate patient:
588	• About medication side effects and what to do should they occur.
589	• <u>Common</u> : diarrhea, dizziness, nausea, headache, fatigue, abnormal dreams,
590	sleep problems, rash, depression.
591	Continue medication
592	Contact care team to discuss symptoms
593	• Schedule an evaluation within one week of contact with care team
594	• <u>Serious</u> : lactic acidosis (weakness, unusual pain, trouble breathing, nausea,
595	vomiting, fast heartbeat, feeling cold/dizzy/lightheaded), liver problems
596	(jaundice, biliuria, light colored stools, lack of appetite, nausea, abdominal
597	pain).
598	Discontinue medication
599	• Contact care team to discuss symptoms that day
600	• Schedule an evaluation within 24 hours of contact with care team

Shifting PrEP Initiation from Practitioner to Nurse

601	• About acute HIV infection symptoms (fever, malaise, myalgia, rash, headache,
602	night sweats, sore throat, lymphadenopathy), and what to do if these should occur.
603	f) <u>Monitoring During Treatment</u>
604	While on PrEP, the patient should be evaluated by the nurse one month after PrEP initiation and
605	every 3 months thereafter. These quarterly visits shall include:
606	• Confirmation of HIV-negative status. This will entail obtaining a 4th generation HIV
607	Antibody/Antigen test (and an HIV VL if the patient is symptomatic for acute HIV
608	infection).
609	• Evaluation of PrEP medication adherence.
610	• Assessment of risk behaviors and provision of risk-reduction counseling and
611	condoms.
612	• Assessment of STI symptoms and, if present, testing and treatment for STIs, as
613	needed (at least every six months).
614	• Three months after initiation, then every six months while on PrEP medication,
615	BUN and serum creatinine should be checked.
616	• In women of reproductive age and trans-males, a pregnancy test and, if pregnant,
617	discussion of continued use of PrEP with patient.